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In Alzheimer’s disease, many indicators point to a central role for poor axonal transport, but the potential
for stimulating axonal transport to alleviate the disease remains largely untested. Previously, we reported
enhanced anterograde axonal transport of mitochondria in 8- to 11-month-old MAPTP301L knockin mice,
a genetic model of frontotemporal dementia with parkinsonism-17T. In this study, we further charac-
terized the axonal transport of mitochondria in younger MAPTP301L mice crossed with the familial Alz-
heimer’s disease model, TgCRND8, aiming to test whether boosting axonal transport in young TgCRND8
mice can alleviate axonal swelling. We successfully replicated the enhancement of anterograde axonal
transport in young MAPTP301L/P301L knockin animals. Surprisingly, we found that in the presence of the
amyloid precursor protein mutations, MAPTP301L/P3101L impaired anterograde axonal transport. The
numbers of plaque-associated axonal swellings or amyloid plaques in TgCRND8 brains were unaltered.
These ﬁndings suggest that amyloid-b promotes an action of mutant tau that impairs axonal transport. As
amyloid-b levels increase with age even without amyloid precursor protein mutation, we suggest that
this rise could contribute to age-related decline in frontotemporal dementia.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia
and is characterized by the presence of amyloid plaques and
neuroﬁbrillary tangles in brain tissue (Masters et al., 2015). Many
studies indicate that axonal transport defects play an important role
in the pathogenesis of AD, and overexpression of tau, whose mu-
tation causes some types of frontotemporal dementia, has also been
reported to impair axonal transport (Bertrand et al., 2013; Ittner
et al., 2008; Majid et al., 2014). Axonal transport is impaired in
several amyloid and tau mouse models, and further impairment of
transport increases pathology (Adalbert and Coleman, 2013; De Vos
et al., 2008; Millecamps and Julien, 2013). These include transgenicr Brain Repair, Department of
ie Site, Robinson Way, Cam-
0; fax: þ44 1223 331174.
dge Drug Discovery Institute,
us, Cambridge CB2 0AH, UK.
Inc. This is an open access articlemouse models overexpressing amyloid precursor protein (APP) or
familial Alzheimer’s disease (FAD) mutant APP (Salehi et al., 2006;
Stokin et al., 2005), mutant presenilin-1 (Lazarov et al., 2007), and
wild-type and frontotemporal dementia with parkinsonism (FTDP)
mutant tau (Ishihara et al., 1999; Zhang et al., 2004). The mecha-
nisms bywhich the pathologic forms of APP, tau, PS1, and amyloid-b
(Ab) disrupt axonal transport are not properly understood. Ab itself
and overexpression of either wild-type and FTDP tau disrupt axonal
transport of a variety of cargoes including mitochondria (Hiruma
et al., 2003; Rui et al., 2006; Stamer et al., 2002; Zhang et al.,
2004). Live-imaging studies of axonal transport in nervous system
tissue have largely focused onmitochondria (Gilley et al., 2012; Mar
et al., 2014; Marinkovic et al., 2012; Milde et al., 2015; Misgeld et al.,
2007). We have reported live imaging of peripheral nerve explants
of mitochondrial transport in a MAPTP301L/P301L knockin mutant
mouse and in normal aging (Gilley et al., 2012; Milde et al., 2015).
Axonal swellings are a pathologic feature common to human AD
and to mice expressing pathogenic forms of APP or tau and mice
expressing ApoE4 (Lewis et al., 2000; Tesseur et al., 2000; Wirthsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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one FAD model, TgCRND8 mice, precede axon loss by many months
and that axonal transport may be disrupted speciﬁcally at these
swellings (Adalbert et al., 2009). TgCRND8 mice inherit a highly
aggressive amyloidopathy caused by the expression of double
mutant amyloid precursor protein (APP; K670N/M671L plus V717F)
(Chishti et al., 2001), leading to early dystrophic neurites and some
cell death (Bellucci et al., 2007). These ﬁndings raise the question of
whether boosting axonal transport can alleviate the pathology.
Until now, very fewmethods have been available to enhance axonal
transport in vivo, and no studies have addressed whether this type
of intervention can alleviate amyloid pathology or the associated
axonal damage. There have been encouraging results using micro-
tubule (MT)-stabilizing agents, such as those used in the treatment
of cancer, to improve axonal transport in tauopathy models
(Brunden et al., 2012; Zhang et al., 2005). These drugs, however,
elicit severe side effects, especially as they have to be administered
on a chronic basis, including axonal damage in peripheral neurop-
athy (Boyette-Davis et al., 2013). In previous work, we have
enhanced axonal transport of mitochondria in young mice without
adverse effects by knocking in the P301L mutation of MAPT (Gilley
et al., 2012), a mutation causing FTDP-17T in humans (Wolfe, 2009).
The effect on axonal transport was reversed as animals aged, sug-
gesting other changes during aging alter how axons react to mutant
MAPT. The mice remained healthy during the normal life span, with
no overt tau pathology, motor, behavioral, or memory deﬁcits. The
initial aim of this study, therefore, was to test whether boosting
axonal transport in young TgCRND8 mice by crossing them to
MAPTP301L knockin mice could alleviate axonal swelling.
We found no alterations in the number of plaque-associated
axonal swellings or the number of amyloid plaques in TgCRND8
brains when MAPT mutation was introduced. However, while we
successfully conﬁrmed the enhancement of axonal transport in
young MAPTP301L/P301L mice and observed a trend in MAPTP301L/þ
mice more representative of FTDP-17T patient genetics, the mito-
chondrial transport in the peripheral nerve axons of TgCRND8 mice
showed a signiﬁcant decrease in the presence of MAPTP301L/P301L,
similar to that found in older MAPTP301L/P301L mice. This suggests
increasing amyloid beta peptide, or other APP processing products
reverses an action of mutant tau on axonal transport and may
contribute to a similar switch observed during normal aging.
2. Material and methods
2.1. Animals
All animal workwas approved by the Babraham Institute Animal
Welfare and Ethical Review Body and UK Home Ofﬁce and carried
out in accordance with the Animals (Scientiﬁc Procedures) Act,
1986, under Project Licenses 80/2254 and 70/7620.
First to conﬁrm whether the enhanced mitochondrial transport
is found in 3-month-old homozygous MAPTP301L knockin mice
(MAPTP301L/P301L), knockin mice were crossed with Mito-P (Thy-1-
mitoCFP-P) mice as previously described (Gilley et al., 2012;
Misgeld et al., 2007). Mito-P mice were kindly provided by Prof.
Martin Kerschensteiner (University Munich) and Prof. Thomas
Misgeld (TU Munich). Heterozygous male TgCRND8 mice (Chishti
et al., 2001) on a 50:50 C57BL/6:129Sv background were bred to
double homozygous MAPTP301L knockin/Mito-P or MAPTP301L
knockin/YFP-H (Thy1.2-YFP-H) (Feng et al., 2000) female mice to
generate triple heterozygotes TgCRND8/MAPTP301L/Mito-P or
TgCRND8/MAPTP301L/YFP-H mice. These triple heterozygotes were
backcrossed to MAPTP301L homozygotes to generate offspring that
were heterozygous for mutant APP and Mito-P (or YFP-H) and
homozygous for MAPTP301L. Those mice which were heterozygousfor Mito-P were used for transport studies, whereas thosewith YFP-
H were used to assess histopathology. Controls without MAPTP301L
knockin were generated by crossing to non-MAPTP301L mice on the
same genetic background. Animals were kept on a 12:12 hours
light:dark cycle at a constant temperature of 19 C in a pathogen-
free environment with up to 5 animals per cage.
2.2. Live imaging of axonal transport and image analysis
Imaging of mitochondrial transport and analysis was performed
as described previously (Gilley et al., 2012; Milde et al., 2015). Brieﬂy,
mitochondrial movements were imaged in sciatic nerve explants
using an Olympus CellR imaging system (IX81 microscope, Hama-
matsu ORCA ER camera, 100 1.45 NA apochromat objective). Pe-
ripheral nerves were used as a surrogate for central nervous system
(CNS) tissue because in our hands quantitative analysis of axonal
transport here is more reproducible than in CNS (Milde et al., 2015),
but the presence of Ab in peripheral nerves was conﬁrmed (Fig. 2).
During imaging, tissues were maintained in oxygenated Neurobasal-
A medium at 37 C in an environment chamber (Solent Scientiﬁc
Ltd). Images were captured using ﬁxed light intensity and camera
exposure time settings at a rate of 2 frames per second for 5 minutes.
Five to 10 individual movies (often containing multiple axons) were
captured for each tissue explant. Individual axons were straightened
using the Straighten plugin in ImageJ software, version 1.44 (Ras-
band, W.S., ImageJ, US National Institutes of Health, Bethesda, MD,
USA; http://imagej.nih.gov/ij/, 1997e2012). Axonal transport param-
eters were determined for individual axons using the Difference
Tracker set of ImageJ plugins (Andrews et al., 2010). The principal
output of these plugins is the number of moving particles identiﬁed
in each frame of the image, normalized to axon length (presented as
particle count per second per 100 mm axon length).
2.3. Histology and staining
Mice were perfused transcardially with 4% phosphate-buffered
paraformaldehyde, and brains and spinal cords processed as pre-
viously described (Adalbert et al., 2009). Sagittal brain sections
were cut at 50 mm, and serial transverse spinal cord sections were
cut at 25 mm through the L3eL5 segments using a Leica CM 1850
cryostat. To stain ﬁbrillar amyloid deposits, brain sections were
incubated in 0.02% Thioﬂavine S in tris-buffered saline (TBS) for 10
minutes and then rinsed in 50% ethanol in TBS and 100% TBS before
mounting in Vectashield Mounting Medium. For motor neuron
analysis, the spinal cord sections were stained with 0.5% cresyl vi-
olet (Adalbert et al., 2006). The excised YFP-H sciatic nerves were
incubated in 1% Triton X-100 (Sigma) in 0.1M PBS for 10 minutes at
room temperature, washed extensively in 0.1M PBS, and then
mounted in Vectashield.
2.4. Microscopy and quantitative/qualitative analysis
The stained sections were imaged with an Olympus FV1000
confocal microscope imaging system using a 40 NA 1.3 or 63 NA
1.4 oil immersion objective. Neuronal structures and amyloid pla-
ques were scanned using a multitrack conﬁguration with laser
excitation (ex.) lines and emission (em.) ﬁlters as follows: Thio-
ﬂavine S 405 nm ex. 475e525 nm em. and YFP 488 nm ex.
505e550 nm em. Single confocal slices or z-stacks at 0.4e0.5 mm
steps were acquired to generate the data images. Conventional
ﬂuorescence imaging was carried out using an Olympus IX 81
inverted microscope coupled to an Olympus U-TV0.5XC digital
camera system. Bright-ﬁeld images of Nissl-stained sections were
acquired using an Olympus BX41 upright microscope (40 objec-
tive) and MicroPublisher 3.3 camera (QImaging).
Fig. 1. Changes in mitochondria transport in TgCRND8 mice homozygous for MAPTP301L tau knockin mutation. Quantiﬁcation of anterograde (A and C) and retrograde (B and D)
mitochondria transport in sciatic nerves from 3-month-old mice with indicated genotypes (all mice are MitoP positive). For all graphs, each data point represents the mean value
obtained for 1 animal (5 ﬁelds of view and, on average, 15 axons per animal). Horizontal bar indicates mean and error bars indicate standard error of the mean. Statistically
signiﬁcant differences between genotypes are indicated (*p < 0.05, **p < 0.01; 1-way analysis of variance with Tukey multiple comparisons posttest). Abbreviation: n.s., not
signiﬁcant.
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determined in 6 sagittal sections (3 sections/hemisphere) as pre-
viously described (Adalbert et al., 2009). Amyloid plaques that had
at least 1 YFP-containing axonal dystrophy (cutoff size of the dys-
trophy 5 mm) in the immediate vicinity were counted as plaques
associated with axonal swellings. Cresyl violetestained motor
neurons with centrally placed nuclei and cytoplasm rich in rough
endoplasmic reticulumwere considered normal morphology. Every
second section from L3eL5 spinal cord segments was qualitativelyFig. 2. Human Ab1e42 is present in peripheral nerves of TgCRND8 mice, and its levels in br
Ab1e42 (ng/g) in sciatic nerves of 3-month-old wild-type (MitoP) and TgCRND8 mice. (B) Bra
for the MAPTP301L knockin mutation. Each data point represents 1 animal (mean and standanalyzed. YFP positive axons from sciatic and tibial nerves with no
fragmentation or swellings along their length were classiﬁed as
intact (Beirowski et al., 2004).
2.5. Ab ELISA
To determine the levels of human Ab1e42 in brain and sciatic
nerve, samples were analyzed using a commercially available ELISA
kit (Life Tech: KHB3441). Brain and sciatic nerves wereain are independent of the MAPTP301L knockin mutation. (A) Concentration of human
in concentration of human Ab1e42 (ng/g) in TgCRND8 and TgCRND8 mice heterozygotes
ard error of the mean, unpaired t test). Abbreviation: n.s., not signiﬁcant.
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tissue) supplemented with 1 Protease Inhibitor Cocktail (Roche)
for 3e4 hours at room temperature. The sample was then frozen
at 20 C until use. Before running in the ELISA, the homogenate
was diluted 1:50 in ice cold reaction buffer (Dulbecco’s PBS þ0.03 %
Tween þ5 % BSA supplemented with 1x Protease Inhibitor Cocktail)
and centrifuged for 20minutes at 4 C at 16,000 g. The supernatant
was then diluted (in the commercial kit dilution buffer) before un-
dergoing ELISA. Brieﬂy, samples were incubated with Ab detection
antibody for 3 hours at RT then thoroughly washed. HRP-conjugated
antibody was added to sample wells for 30 minutes. After another
wash step, samples were incubated with stabilized chromogen for
30 minutes. The reaction was stopped using an acid-based stop so-
lution and absorbance read at 450 nm using a PheraStar FS plate
reader. Samples were run with a standard curve (4-parameter ﬁt) to
obtain a concentration readout. Final concentration is given as ng of
Ab per gram of tissue (Harwell and Coleman, 2016).
2.6. Immunohistochemistry and Gallyas staining
Mouse brains were ﬁxed in 10% formalin for 24 hours before
embedding in parafﬁn. Then, 7-mm-thick tissue sections were
stained with the Gallyas silver staining method to identify neuro-
ﬁbrillary tangles as reported previously (Gilley et al., 2012;
Kuninaka et al., 2015). They were examined with a Zeiss Axioplan
microscope, and digital images were acquired using an AxioCam
HRc camera.
The immunohistochemical labeling was performed using the
ABC method. Sections were treated with 0.3% H2O2 to inhibit
endogenous peroxidase and then blocked in 10% vol/vol normal
horse serum in TBS (0.01 M Tris, 0.15 M NaCl, pH 7.4). After
overnight incubation with diluted PHF-1 or AT8 antibodies (Inno-
genetics), sections were incubated with biotin-conjugated horse
anti-mouse antibodies followed by ABC complex (Vector Labora-
tories, Burlingame, CA, USA). Peroxidase activity was developed
using diaminobenzidine as chromogen.
2.7. Statistical analysis
Statistical tests, as described in the ﬁgure legends, were per-
formed using Prism software (GraphPad Software Inc, La Jolla, CA,
USA). A p value of >0.05 was considered not signiﬁcant (ns), and
*p < 0.05, **p < 0.01, and ***p < 0.001 was signiﬁcant.
3. Results
3.1. Enhanced mitochondrial transport in 3-month-old
MAPTP301L/P301L knockin mouse peripheral nerves
First, we wanted to conﬁrm whether the enhanced mitochon-
drial transport found previously in 8e11 months homozygous
MAPTP301L tau knockin mice (Gilley et al., 2012) was also present in
younger, 3-month-old homozygous tau knockin mice, an age when
TgCRND8 shows substantial axonal swellings and an increasing
plaque density (Adalbert et al., 2009). To test this, we crossed
MAPTP301L knockin mice to Thy-1-mitoCFP-P (Mito-P) mice, which
have CFP-labeled mitochondria in a subset of their neurons
(Misgeld et al., 2007). The transport of CFP-labeled mitochondria
was assessed in axons of explanted sciatic nerves from 3-month-old
MAPTP301L/P301L, MAPTP301L/þ, andMAPTþ/þmice. Peripheral nerves
were used because we ﬁnd quantitative analysis of axonal transport
in nerves is more reproducible than that in CNS (Milde et al., 2015).
We found that the number of CFP-labeled mitochondria moving in
an anterograde directionwas signiﬁcantly higher in MAPTP301L/P301L
mice relative towildtypes (Fig 1A). InMAPTP301L/þmice, therewas atrend toward increased mitochondrial transport, but the difference
was not statistically signiﬁcant. No signiﬁcant differences were
found for retrograde transport (Fig 1B), and changes in anterograde
ﬂux were not accompanied by signiﬁcant alterations to maximum
speed or average speed (not shown). Thus, axons from young 3-
month-old MAPTP301L/P301L knockin mice show an increase in
anterograde mitochondrial ﬂux, similar to older (8e11 months)
mice, prior to the reversal of this effect we have previously
observed in old age (Gilley et al., 2012).
3.2. In the presence of the TgCRND8 mutation, MAPTP301L/P301L
reduces the axonal transport of mitochondria
Next, we assessed whether the presence of MAPTP301L knockin
mutation, alters themitochondrial transport in TgCRND8 peripheral
axons. Instead of the expected enhancement, we observed a sig-
niﬁcant decrease in anterograde mitochondrial ﬂux in 3-month-old
TgCRND8 mice homozygous for the MAPTP301L knockin mutation
(TgCRND8/MAPTP301L/P301L) (Fig 1C), reminiscent of old
MAPTP301L/P301L mice without mutant APP (Gilley et al., 2012).
Retrograde mitochondrial transport also declined, but this was not
statistically signiﬁcant in our sample (Fig 1D), and average speed of
transport was unaltered (not shown). No signiﬁcant differences in
any transport parameters were identiﬁed for TgCRND8 mice het-
erozygous for the tau knockin mutation (TgCRND8/MAPTP301L/þ).
These data indicate that in the presence of the TgCRND8 mutation,
the effect of MAPTP301L/P301L on axonal transport of mitochondria in
young animals is reversed, suggesting an interaction between Ab, or
other APP processing products, and mutant tau that resembles the
effect of normal aging.
3.3. Ab1e42 is present in peripheral nerves of TgCRND8 mice and
Ab1e42 level in brain is not altered by MAPT
P301L/þ
Using ELISA, we quantiﬁed the Ab1e42 in sciatic nerves from
young (3 months) TgCRND8 mice and found that Ab1e42 is present
in peripheral nerves, at the age when the axonal transport mea-
surements were conducted (Fig. 2A). However, the levels were less
than 10% of those in brain of the same animals (Fig. 2B). This sug-
gests that the use of peripheral nerves as a surrogate for CNS tissue
in this study could underestimate the effect of Ab, or other APP
processing products, in combination with tau in the CNS. Brain
levels of Ab were not altered by the presence of the MAPTP301L/þ
knockin mutation (Fig. 2B).
3.4. MAPTP301L/P301L knockin mutation does not reduce the number
of plaques and the associated axonal swellings in TgCRND8 brains
To test whether the presence of MAPTP301L knockin mutation
ameliorates amyloid-associated pathology, we quantiﬁed the
number of amyloid plaques and the number of plaque-associated
axonal swellings in the brains of TgCRND8/MAPTþ/þ/YFP-H and
TgCRND8/MAPTP301L/P301L/YFP-H mice at 3 months of age. We
found that the MAPTP301L/P301L mutation did not signiﬁcantly
reduce the number of amyloid plaques (Fig 3A, C) or the associated
axonal swellings in the brains of TgCRND8 mice (Fig 3B, D).
Although as axonal transport was not enhanced in these animals as
expected, it remains undetermined whether boosting transport can
alleviate axonal swellings.
3.5. No morphologic alterations are present in TgCRND8/
MAPTP301L/P301L spinal cord motor neurons and peripheral nerves
Histologic analysis of motor neurons from lumbar spinal cord
segments L3-L5 and YFP positive axons from sciatic and tibial nerves
Fig. 3. Homozygous MAPTP301L knockin mutation does not reduce the number of plaques and the associated neurite swellings in TgCRND8 brains. (A) Amyloid plaques (arrows) in
the cortex of 3-month-old TgCRND8 mouse and (B) a single amyloid plaque associated with neurite dystrophy (arrow). Quantiﬁcation (mean and standard error of the mean,
unpaired t test; n ¼ 5) of the number of plaques (C), and plaques with associated dystrophy (D) reveals no signiﬁcant difference (ns) between TgCRND8 and TgCRND8/
MAPTP301L/P301L mice. Blue: Thioﬂavin S; Green: YFP in B. Scale bar: A, 100 mm; B, 20 mm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the Web version of this article.)
R. Adalbert et al. / Neurobiology of Aging 68 (2018) 68e7572showed no obvious alterations in 3-month-old TgCRND8/MAPTP301L/
P301Lmice. Cresyl violet staining revealedmotor neuronswith normal
morphology with centrally placed nuclei and a cytoplasm rich in
rough endoplasmic reticulum (Fig 4A). Also, YFP positive axons from
sciatic and tibial nerves were intact with no fragmentation or
swellings along their length (Fig 4B, C). These observations show that
the reduced anterograde axonal transport of mitochondria in pe-
ripheral nerves of TgCRND8/MAPTP301L/P301L mice occurs in
morphologically normal axons and spinal cord motor neurons.
3.6. Absence of tau pathology
We previously showed that pathologic aggregation of hyper-
phosphorylated tau does not occur in MAPTP301L/P301L tau knockin
mice (Gilley et al., 2012). Similarly, in this study, no Gallyas-
positive neurons or neuronal PHF-1 immunostaining for phos-
phorylated tau was detected in 6-month-old brains even after
combining TgCRND8 transgene with MAPTP301L/P301L or
MAPTP301L/þ knockin mutation (Fig 5). Only a puncta-like staining
of dystrophic neurites around the congo red positive plaques was
found (Fig 5A). Hence, the presence of FAD-APP does not induce
tau pathology in MAPTP301L tau knockin mice, at least up to the
age of 6 months.Fig. 4. Morphologically intact spinal cord motor neurons and peripheral nerves in 3-month
through the L3-L5 lumbar spinal cord segment. (B) YFP positive axons from sciatic and (C) ti
color in this ﬁgure legend, the reader is referred to the Web version of this article.)4. Discussion
In this study, we conﬁrmed and extended our previous obser-
vation of increased anterogrademitochondrial transport in 8- to 11-
month-old homozygousMAPTP301L knockinmice (Gilley et al., 2012)
to 3-month-old homozygous knockinmice (Fig 1A) and to a trend in
the same direction in heterozygotes. Retrograde transport (Fig 1B),
maximum speed or average speed in either direction (not shown)
were unaltered, and after crossing to TgCRND8, the numbers of
plaque-associated axonal swellings or amyloid plaques in TgCRND8
brains were neither reduced nor increased by MAPTP301L/P301L.
By crossing the MAPTP301L knockin mice with an FAD model,
TgCRND8 mice, our initial aim was to test whether boosting axonal
transport can alleviate axonal swellings. We have selected TgCRND8
mice for our study as they develop robust axonal swellings at an
early stage in amyloid pathology that we have extensively charac-
terized, preceding axon and cell death, and major loss of synapses
(Adalbert et al., 2009). Although these features arise in young ani-
mals, they closely resemble those in an aging human AD brain.
Therefore, it is reasonable to use this model to test whether they
can be alleviated by boosting axonal transport. These axonal
swellings contain accumulations of fragmented mitochondria and
other organelles, which suggest impairment of axonal transport.-old TgCRND8/MAPTP301L/P301L mice. (A) Cresyl violet (Nissl)-stained transverse section
bial nerves. Scale bar: A, 20 mm; B and C, 50 mm. (For interpretation of the references to
Fig. 5. No tau histopathology in the brains of 6-month-old TgCRND8 mice homozygous for MAPTP301L tau knockin mutation. (A, B) PHF1 immunostaining in the cortex showed only
puncta-like staining of dystrophic neurites (arrow) around the congo red positive plaques (star) with no neuronal staining in the mouse frontal cortex of TgCRND8 (A) or TgCRND8/
MAPTP301L/P301L (B). (CeF) Gallyas silver staining. No NFTs was present in the mouse brains of TgCRND8 (C) or TgCRND8/MAPTP301L/P301L (D). Tg30 tau transgenic mouse brain
expressing human P301S/G272V mutant tau (Leroy et al., 2007) (E) or human AD tissue (F) acting as positive control for NFT and dystrophic neurites around amyloid plaque (star).
Scale bars: 20 mm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
R. Adalbert et al. / Neurobiology of Aging 68 (2018) 68e75 73Therefore, “unblocking” these swellings could alleviate AD-like
histopathology and symptoms in TgCRND8 mice. Surprisingly, the
presence of the homozygous MAPTP301L mutation signiﬁcantly
decreased the anterograde mitochondrial ﬂux in 3-month-old
TgCRND8 mice instead of enhancing it as we initially hypothesized,
so it remains untested at present whether increasing axonal
transport could alleviate plaques and/or axonal swellings.
Previous studies indicated that the physiological function of
tau is required for aspects of FAD-APP pathogenesis. The block of
axonal transport by Ab1e42 oligomers in hippocampal primary
cultures requires the presence of tau (Vossel et al., 2010), and
FAD-APPeinduced behavioral deﬁcits in mice are alleviated by
removing tau (Roberson et al., 2007). Recently, it was also re-
ported that mutant tau with markedly reduced MT-binding ca-
pacity still enabled Ab-induced axonal transport deﬁcits (Vossel
et al., 2015). We now show that co-expression of MAPTP301L,
even at physiological levels, synergistically impairs axonal
transport with FAD-APP. All these studies suggest that different
tau genotypes, in the presence of Ab, can lead to transport
impairment.
Our ﬁndings support the hypothesis that Ab and tau converge in
axons to inﬂuence axonal transport or that tau itself is a down-
stream target of Ab on the same pathway. Previously, it was sug-
gested that tau may lie downstream of APP/Ab or on a necessary
pathway that converges onto a common, downstream target
(Karran et al., 2011; Morris et al., 2011). In different neurodegen-
erative diseases, both in humans and in mice, plaques and tangles
can arise independently of one another. In mice, neither FAD-APP
nor FTDP-17T mutant tau causes both of these pathological hall-
marks. Some human patients show amyloid without tau pathology,
and FTDP-17T tau mutations cause tangles without plaques in
frontotemporal dementia. These observations are consistent with
convergent disease pathways, either of which can cause pathology
when sufﬁciently activated. MAPTP301L knockin mutation does not
enhance the generation of Ab1e42 in the brains of 3-month-old
TgCRND8 mice (Fig 2B), consistent with previous results using
overexpression of tau in FAD-APP expressing cell lines or primaryneuronal cultures (Goldsbury et al., 2006). In addition, when tau
deletion reduced cognitive deﬁcits and excitotoxic damage in FAD-
APP mice, there was no corresponding reduction in Ab1e42
(Roberson et al., 2007). This ﬁnding is important because if the
synergistic effect of MAPTP301L knockin tau and FAD-APP were
mediated by increasing Ab1e42 processing, then that would favor a
mechanism involving feedback on APP over a common downstream
target for Ab1e42 and MAPTP301L tau.
Tau pathology is not a feature of APP or PS1 mutant mice but has
been seen when combined with overexpressing tau mutants. We
were interested to see whether such pathology could be induced
when mutant tau is expressed at physiological levels. The over-
expression of Ab did not induce pathologic aggregation of hyper-
phosphorylated tau in MAPTP301L tau knockin mice by the age of
6 months; however, we cannot rule out the possibility that tau
pathology could develop at an older age. The puncta-like staining of
phosphorylated tau in dystrophic neurites around the plaques we
observed in our study (Fig. 5A,B) was reported previously in mutant
APP and APP/PS1 transgenic mice, therefore is unlikely to reﬂect an
action of MAPT mutation (Boutajangout et al., 2004; Kurt et al.,
2003; Tomidokoro et al., 2001).
It is worth noting that alternative models that overexpress both
mutant APP andMAPTP301L show late development of tau tangles; a
double transgenic requiring 9 months and a different 3Tg model
not showing pathology until 12 months of age (Lewis et al., 2001;
Oddo et al., 2003). It may be due to the knockin nature of the
MAPTP301L in our model that neuroﬁbrillary pathology cannot
develop during the normal life span of our mice.
Some evidence suggests that increased tau expression and/or
altered tau isoform ratio aremore important for the development of
neuroﬁbrillary pathology in a mouse than is the presence of an
FTDP-17T mutation (Adams et al., 2009; Gotz et al., 2001). The
presence of tau at physiological levels and with the expected iso-
form ratios in our MAPTP301L tau knockin mice could be responsible
for the absence of tau pathology. In addition, it could be thatmurine
tau has less propensity for aggregation in vivo compared to human
tau (Allen et al., 2002; Ando et al., 2011; Sahara et al., 2002).
R. Adalbert et al. / Neurobiology of Aging 68 (2018) 68e7574The decline in axonal transport seen when combining the APP
and MAPTP301L mutations may anticipate the age-related effect of
MAPTP301L tau mutation alone. As Ab levels increase with age even
without APP mutation (Lesne et al., 2013), our double mutants may
have modeled this process in younger animals. Thus, we suggest
that this Ab rise could contribute to age-related decline in fronto-
temporal dementia. It would be important to repeat our observa-
tions with other mutant tau knockin mice (e.g., R406W) as well, to
knowwhether axonal transport impairment in the presence of Ab is
a consistent effect of FTDP tau mutations. In addition, it would be
interesting to test whether amyloid-independent pathogenic
mechanism can also lead to axonal transport impairment observed
in our model, by crossing the MAPTP301L tau knockin mice with
wild-type human APP overexpressing mice (Mucke et al., 2000). In
these mice, the human wild-type APP processing is basically non-
amyloidogenic (Simon et al., 2009).
Using our mouse model, we found that Ab1e42 is present in
peripheral nerves at the age when the axonal transport measure-
ments were done (Fig. 2A), similar to previous studies in the pe-
ripheral nerves of other APP mutant mice (Jolivalt et al., 2012). In
our model, the Ab1e42 levels in the peripheral nerves were less than
10% of those in the brains of the same animals, which suggest that
the effect of Ab in combination with tau in the CNS could be much
stronger.
In the presence of the APP mutation, MAPTP301L/P301L knockin
failed to enhance axonal transport of mitochondria; therefore, new
strategies have to be used to increase transport (Hinckelmann et al.,
2013). Drugs increasing MT acetylation may be useful to boost
axonal transport in AD. Tubulin acetylation is reduced in the brains
of patients with AD (Hinckelmann et al., 2013) and in the brains of
various mouse models of AD (Govindarajan et al., 2013; Kim et al.,
2012). Studies so far showed that HDAC6 inhibitors reverse the
amyloid betaeinduced changes in a-tubulin acetylation and mito-
chondrial trafﬁcking in cultured hippocampal neurons (Kim et al.,
2012) and HDAC6 knockout in a mouse model of AD restores a-
tubulin acetylation in the brain and cognitive function in AD mice
(Govindarajan et al., 2013). Another approach to improve axonal
transport could be to inhibit cJun N-terminal kinase (JNK) activity.
JNK hyperactivity has been reported in models of AD, and the in-
hibition of JNK activity in vivo was shown to be neuroprotective in
animal models (Mehan et al., 2011). JNK3 inhibition rescued axonal
transport defects induced by pathogenic fragments of huntingtin in
a squid model of axonal transport (Morﬁni et al., 2009).
In summary, we conﬁrmed and extended our previous obser-
vation of an increase in mitochondrial transport in young
MAPTP301L knockin homozygous mice to animals aged 3 months
and observed a nonsigniﬁcant trend also in heterozygotes. This
could represent early consequences of the tau dysfunction that may
be relevant to FTDP-17T pathogenesis in humans as they age. Our
results demonstrate that TgCRND8 and MAPTP301L/P301L mutations
in combination reduce the axonal transport of mitochondria in
peripheral nerves, in contrast to the enhancement of transport in
young MAPTP301L/P301L mice. This exciting ﬁnding suggests that Ab
and tau converge in axons to inﬂuence axonal transport or that tau
itself is a downstream target of amyloid beta on the same pathway.
MAPTP301L mutation did not signiﬁcantly reduce the number of
plaque associated axonal swellings or the number of amyloid pla-
ques in TgCRND8 brains and did not alter Ab levels in brain. Our
FAD-APP andMAPTP301L tau knockin mouse model may be useful to
study how amyloid beta peptide and tau combine in pathogenesis.Disclosure statement
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